Strong ties with research institutions

Innovation has been at the heart of bioMérieux’s strategy since the Company’s beginnings. This mindset of being open to new possibilities is developed through international, multidisciplinary public and private-sector collaborations with academic research organizations, the medical and scientific community, and cutting-edge biotech companies.

In China

At the conclusion of our ten-year collaboration with Fudan University Shanghai Cancer Hospital, we created a new joint research laboratory with the Shanghai Children’s Medical Center. A three-year collaboration agreement signed in early 2019 will initially focus on a clinical study concerning the use of the NEPHROCHECK® test for the early risk assessment of acute kidney injuries (AKI) in young children.

In Brazil

Based on the model of the research program ANTOINE (bioMarkers to differeNtiate bacTerial frOm vIral iNfEctions) conducted in conjunction with the Lyon Civil Hospitals (HCL) in France, bioMérieux has worked with Infants Institute of São Paulo in Brazil to launch the ANTONIO project for children under age three admitted to the Emergency Room with febrile illness. This research aims to identify biomarkers that will help exclude a bacterial infection and guide the prescription of antibiotics.

In France

With the Lyon Civil Hospitals (HCL)

bioMérieux and HCL have begun a new project, in addition to the ANTOINE research program launched in 2017 by the bioMérieux-HCL joint research laboratory located at the Lyon Sud Hospital, focusing on the diagnosis of severe bacterial infections in children admitted to the Emergency Room. The new project involves a study of the NEPHROCHECK® test for the early risk assessment of acute kidney injuries (AKI) among patients with multiple injuries, presenting a profile similar to that of sepsis patients, and who are treated in intensive care at Edouard Herriot Hospita.

With the French Technology Innovation Institute in Microbiology (BIOASTER – Lyon, France)

  • The research program known as REALISM (REAnimation Low Immune Status Markers) was launched in October 2016 by bioMérieux, the College of Industrial Physics and Chemistry of the City of Paris (ESCPI), GSK, Lyon Civil Hospitals (HCL) and Sanofi to improve the management of patients with a high risk of sepsis. The project was completed in 2018 and interpretation of the study results is taking place in 2019.
  • The CODIRA 2 project (Optical characterization for the rapid diagnosis of bacterial infections) that began in 2017 with BIOASTER and the Clinique des Cèdres (Échirolles, France), focusing on the ultra-rapid diagnosis of infectious diseases, was completed in 2018.
  • In late 2018, the DIREX research project was launched to study rapid microbiology using automated readers to detect Gram-positive and Gram-negative bacteria, an important step in the identification of pathogens.
  • bioMérieux and BIOASTER are partners in the ISIT-TB project, which was launched in 2018 to identify biomarkers for the diagnosis of tuberculosis. Among patients who have been exposed to the tuberculosis bacterium, the project aims to determine which patients are likely to develop active tuberculosis, and how each patient responds to treatment. At the same time, molecular markers are being prototyped on the BIOFIRE® FILMARRAY® platform.